A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.
Proc Natl Acad Sci U S A
; 119(12): e2200065119, 2022 03 22.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1740535
ABSTRACT
SignificanceConcern has increased about the pandemic potential of Nipah virus (NiV). Similar to SARS-CoV-2, NiV is an RNA virus that is transmitted by respiratory droplets. There are currently no NiV vaccines licensed for human use. While several preventive vaccines have shown promise in protecting animals against lethal NiV disease, most studies have assessed protection 1 mo after vaccination. However, in order to contain and control outbreaks, vaccines that can rapidly confer protection in days rather than months are needed. Here, we show that a recombinant vesicular stomatitis virus vector expressing the NiV glycoprotein can completely protect monkeys vaccinated 7 d prior to NiV exposure and 67% of animals vaccinated 3 d before NiV challenge.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Vacunas Virales
/
Vacunas Sintéticas
/
Enfermedades de los Primates
/
Virus Nipah
/
Infecciones por Henipavirus
Tipo de estudio:
Estudios diagnósticos
/
Estudio pronóstico
Tópicos:
Vacunas
Límite:
Animales
Idioma:
Inglés
Revista:
Proc Natl Acad Sci U S A
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS